Urgent.News

What's breaking now, across thousands of outlets.

Health & Medicine

An orexin drug’s ‘proof-of-concept’ in ADHD; Cue’s ‘unwarranted’ share slide

Alkermes’ results heightened anticipation for a coming readout in 2027. Elsewhere, AbbVie leaned into AI drug discovery and the FDA expanded use of Eli Lilly’s breast cancer pill.

We haven't written up this one. BioPharma Dive has the full story — the link below goes straight to it.

Read the original at biopharmadive.com →

More in Health & Medicine

More from Tuesday 22 September →